WASHINGTON - U.S. biotechnology firm Moderna Inc. said Thursday its coronavirus vaccine maintained 93 percent efficacy through six months after the second shot, but pointed to the likelihood of the need for a third booster shot in the fall.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
